Context Therapeutics’ (CNTX) Buy Rating Reaffirmed at HC Wainwright

Context Therapeutics (NASDAQ:CNTX)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They presently have a $6.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 206.12% from the company’s previous close.

Context Therapeutics Trading Down 5.8 %

NASDAQ CNTX opened at $1.96 on Monday. Context Therapeutics has a 12 month low of $0.77 and a 12 month high of $2.75. The stock has a market cap of $147.00 million, a price-to-earnings ratio of -1.47 and a beta of 2.31. The company’s 50 day moving average is $2.31 and its two-hundred day moving average is $1.90.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Wednesday, August 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.04. Sell-side analysts forecast that Context Therapeutics will post -0.31 EPS for the current year.

Institutional Trading of Context Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Opaleye Management Inc. bought a new position in Context Therapeutics during the fourth quarter valued at approximately $1,102,000. Renaissance Technologies LLC grew its holdings in shares of Context Therapeutics by 63.4% in the second quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock valued at $131,000 after purchasing an additional 25,300 shares in the last quarter. Ally Bridge Group NY LLC increased its position in Context Therapeutics by 159.8% in the second quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock worth $3,782,000 after purchasing an additional 1,160,281 shares during the last quarter. Great Point Partners LLC purchased a new stake in Context Therapeutics during the second quarter valued at $14,876,000. Finally, Affinity Asset Advisors LLC raised its stake in Context Therapeutics by 392.4% during the second quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock valued at $3,246,000 after purchasing an additional 1,290,323 shares in the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.